The BRCA Gene Test: Who Should Consider It and What Results Change

It often starts at a kitchen table. Someone pulls out old photos after a funeral and realizes the pattern nobody said out loud: a grandmother gone at 52, two aunts with breast cancer before 50, a cousin with ovarian cancer at 41. That moment, when a family story suddenly looks like a family pattern, is what sends most people to ask about genetic testing.

Roughly 1 in 400 people in the general population carries a harmful BRCA1 or BRCA2 variant. Among people of Ashkenazi Jewish descent, it’s closer to 1 in 40. Most carriers have no idea, because the gene itself causes no symptoms. It simply waits in the family tree.

Here’s the honest version of what this test can and cannot tell you, who genuinely benefits from it, and, the part most articles skip, exactly what changes the day your results come back.

What does the BRCA gene test actually look for?

Start with a fact that surprises people: everyone has BRCA1 and BRCA2 genes. They aren’t “cancer genes”: they’re cancer protection genes. Their job is repairing broken DNA, specifically the double-strand breaks that accumulate in cells over a lifetime. When the repair crew works, damaged cells get fixed or shut down. When one copy of the gene carries a harmful inherited change, that repair system is weakened from birth, and errors can pile up in breast, ovarian, prostate, and pancreatic tissue faster than the body can manage.

The test itself is unglamorous: a tube of blood or a saliva sample, sent to a laboratory that reads the DNA sequence of both genes letter by letter, looking for changes known to disable them. Results typically come back in two to four weeks.

One important shift in recent years: clinicians rarely order a BRCA-only test anymore. Most now use multi-gene panels that check BRCA1 and BRCA2 alongside other genes tied to hereditary breast and ovarian cancer, such as PALB2 and CHEK2. That matters, because a meaningful share of hereditary cancer in families with “BRCA-looking” histories traces to genes other than BRCA. If you were tested before roughly 2014, ask whether an updated panel makes sense: the technology has moved considerably.

How much do BRCA1 and BRCA2 mutations raise cancer risk?

The numbers deserve to be stated plainly, because vague phrases like “increased risk” help no one. According to the National Cancer Institute, here is how lifetime risk (roughly to age 70–80) compares:

Cancer type	General population (women)	BRCA1 carrier	BRCA2 carrier
Breast cancer	About 13%	55–72%	45–69%
Ovarian cancer	About 1.2%	39–44%	11–17%

Read those ranges carefully, because they carry two honest caveats. First, they are ranges, not fixed destinies, actual risk varies with the specific variant, family history, and factors researchers are still mapping. Second, and this is the sentence worth remembering: a substantial share of carriers never develop cancer at all. A 60% risk means 40 out of 100 carriers won’t get that cancer.

BRCA variants also raise risks beyond breast and ovarian cancer, including pancreatic cancer, prostate cancer in men, and melanoma with certain BRCA2 changes. The elevations there are smaller in absolute terms but real, which is why a positive result reshapes screening for the whole body, not just one organ.

Who should consider BRCA testing?

Not everyone benefits from this test, and mainstream guidelines are candid about that. Population-wide BRCA screening isn’t currently recommended; testing earns its keep when the odds of finding something meaningful are reasonably high. The U.S. Preventive Services Task Force and CDC point to specific red flags:

• Breast cancer diagnosed in you or a close relative before age 50
• Triple-negative breast cancer at any age
• Ovarian, fallopian tube, or primary peritoneal cancer in the family, at any age
• Male breast cancer anywhere in the family
• Pancreatic cancer or metastatic prostate cancer in close relatives
• Multiple relatives on the same side with breast, ovarian, prostate, or pancreatic cancer
• Ashkenazi Jewish ancestry, even with a thinner family history
• A relative who has already tested positive for a BRCA or related variant

Notice what’s not on the list: a single grandmother with breast cancer at 78. Breast cancer is common enough, about 1 in 8 women over a lifetime, that one late-life case usually reflects ordinary risk, not an inherited syndrome.

If any of those flags fit your family, the recommended first step isn’t the test itself. It’s a conversation with a genetic counselor or a clinician trained in cancer genetics, who can map your pedigree and tell you whether testing is likely to yield useful information, and who in the family should ideally be tested first.

Which parent passes down the BRCA gene?

Either one. This trips up more families than almost anything else in cancer genetics. Because BRCA variants are famous for breast and ovarian cancer, people instinctively check only their mother’s side. But BRCA1 and BRCA2 sit on chromosomes 17 and 13, ordinary chromosomes that both parents pass down equally. A father carries and transmits a BRCA variant exactly as often as a mother does.

The inheritance pattern is autosomal dominant: if one parent carries the variant, each child, son or daughter, has a 50% chance of inheriting it. A coin flip, run fresh for every pregnancy. One sibling can carry it while another doesn’t.

Here’s why the father’s side hides so well. A man with a BRCA2 variant may never develop cancer himself, or may develop prostate cancer in his seventies that no one connects to genetics. If his branch of the family happens to be mostly men, the variant can travel silently for two or three generations before surfacing in a granddaughter’s early breast cancer. Geneticists sometimes call this a variant that “skipped” generations: it didn’t skip anything; it just moved through people whose cancers were less visible or never developed.

Practical takeaway: when a counselor takes your family history, give both sides equal airtime. Prostate cancer in a paternal uncle and pancreatic cancer in a paternal grandfather belong in the conversation just as much as an aunt’s breast cancer.

At what age should you be tested for the BRCA gene?

There’s no single magic birthday, but there is a sound principle: test when the result could change what you do. For most people at elevated risk, that window opens in early adulthood.

Guidelines generally discourage testing minors. A BRCA result changes nothing about a 12-year-old’s medical care, enhanced screening for carriers doesn’t begin until about age 25, and it saddles a child with heavy information they didn’t choose. Adults can weigh that trade-off; children can’t. Most clinics test at 18 or older, and many counselors gently suggest the mid-20s, when the results start driving real decisions.

Why the mid-20s? Because that’s when the first concrete action kicks in: for confirmed carriers, breast screening with MRI typically starts at 25. Knowing your status by then means you never miss the on-ramp. Testing by your early 30s also leaves room for family-planning conversations, since some carriers factor genetics into decisions about the timing of children or preventive surgery.

What about testing at 50, 60, or beyond? Still worthwhile. Ovarian cancer risk in BRCA1 carriers climbs steeply after 40, prevention options remain relevant at nearly any age, and, often the deciding factor, an older adult’s result tells children and grandchildren whether they need testing at all. Plenty of grandparents get tested less for themselves than for the generations behind them.

Why genetic counseling comes before the blood draw

The appointment most people skip in their imagination turns out to be the most valuable one. Before any sample is taken, a genetic counselor spends 30 to 60 minutes building a three-generation family tree: who had which cancer, at what age, on which side. That pedigree does two jobs. It estimates how likely a harmful variant is in your family, and it identifies the smartest person to test first.

That second point is counterintuitive. If your mother survived breast cancer at 45 and she’s willing, testing her first is often more informative than testing you. If she carries a variant, the lab knows exactly what to look for in your DNA, and if you then test negative for her specific variant, that’s a true all-clear rather than a murky one. Skip this step, and a negative result on your own test means far less than you’d hope.

Counseling also covers the ground people don’t anticipate: what a variant of uncertain significance would mean, how results affect life insurance applications, how to tell siblings, whether your existing anxiety about cancer will get better or worse with information in hand. Sessions increasingly happen by phone or video, which has removed most of the old access barriers.

The test itself is anticlimactic by comparison: a blood tube or a saliva kit, then a two-to-four-week wait.

What happens if a BRCA test is positive?

First, breathe. A positive result is not a diagnosis, and it’s not a countdown clock. It’s a risk statement, and, importantly, it unlocks options that people at average risk don’t get. Broadly, they fall into three lanes.

Intensified screening. Carriers typically begin annual breast MRI at 25, adding mammography around 30, often alternating the two every six months so no twelve-month stretch goes unexamined. The goal is blunt: if cancer develops, catch it at a stage where outcomes are best. Screening for pancreatic and prostate cancer may be added depending on the variant and family history.

Risk-reducing surgery. The numbers here are striking. Preventive mastectomy lowers breast cancer risk by roughly 90% or more. Removing the ovaries and fallopian tubes, usually discussed between ages 35 and 40 for BRCA1 carriers and 40 to 45 for BRCA2, after childbearing decisions, sharply cuts ovarian cancer risk, a disease with no reliable screening test. These are major, personal decisions, not obligations, and many carriers choose surveillance instead for years.

Medication and family cascade. Risk-reducing medications exist and are worth discussing with your care team. And a positive result becomes a gift to relatives: each sibling and child has a 50% chance of carrying the same variant, and their testing, called cascade testing, is simpler and cheaper because the lab knows the target.

One more thing: if a carrier does develop cancer, knowing BRCA status can shape treatment planning. That’s a conversation for an oncology team, but the information has therapeutic weight, not just preventive weight.

A negative result isn't always the all-clear

This is where honest reporting matters most, because “negative” comes in two very different flavors.

A true negative happens when your family’s harmful variant is already known, say, your mother tested positive for a specific BRCA1 change, and your test shows you didn’t inherit it. That’s genuinely reassuring. Your risk drops back to roughly the general population’s, and standard screening guidelines apply. You also cannot pass on a variant you don’t carry, so your children are in the clear on that branch.

An uninformative negative happens when no one in your family has an identified variant, and your test finds nothing. It sounds like the same news. It isn’t. Your family’s cancer pattern still exists, and it may be driven by a gene the panel didn’t cover, a variant science hasn’t yet characterized, or a combination of many small genetic and environmental factors that no single test detects. Roughly 5 to 10% of breast cancers are linked to known inherited variants, meaning a strong family history can carry real risk even with clean genetic results.

The practical consequence: after an uninformative negative, clinicians often still recommend enhanced screening based on family history alone, using risk-calculation models rather than gene results. A negative test is a data point, not a discharge letter. If your family history is heavy, keep acting like it.

What is a "variant of uncertain significance", and why you shouldn't act on it

Somewhere between positive and negative sits the result nobody warns you about: the variant of uncertain significance, or VUS. The lab found a change in your BRCA gene, but science doesn’t yet know whether that particular change is harmful or harmless. Depending on the panel and your ancestry, a VUS turns up in a meaningful minority of tests, and it’s more common in people from populations underrepresented in genetic databases.

The universal guidance from genetics professionals is emphatic: do not make medical decisions based on a VUS. No preventive surgery, no assumption of high risk. Here’s the reassuring statistic behind that rule, when a VUS is eventually reclassified, the large majority turn out to be benign. Human genomes are peppered with harmless quirks; most spelling differences in a gene don’t break it.

What a VUS does require is patience and a forwarding address. Laboratories periodically reanalyze variants as evidence accumulates, and reclassifications happen, sometimes years later. A few practical moves:

• Ask your counselor how the lab handles reclassification notices, and confirm they have your current contact information.
• Check in every couple of years, especially before any major medical decision.
• Base your screening plan on family history in the meantime, exactly as you would after an uninformative negative.

A VUS feels like limbo, and emotionally it is. Medically, the evidence says to treat it as a question mark, not an alarm.

Do men need BRCA testing too?

Yes, and the fact that this question still needs asking says a lot about how BRCA gets framed. Men inherit BRCA variants at exactly the same rate as women, pass them to sons and daughters at exactly the same 50% rate, and face real health consequences of their own.

The numbers: a man with a BRCA2 variant has roughly a 6 to 7% lifetime risk of breast cancer, small compared with women’s risk, but about 60 times higher than the average man’s. BRCA2 also raises prostate cancer risk substantially, and BRCA-related prostate cancers tend to appear earlier and behave more aggressively. Pancreatic cancer risk rises as well, particularly with BRCA2.

What changes for a man who tests positive? Typically: breast self-awareness and annual chest-wall exams starting around 35, earlier and more deliberate prostate cancer screening conversations (often beginning at 40), and, with a family history of pancreatic cancer, possible enrollment in pancreatic surveillance programs. None of it is dramatic; all of it is earlier and more attentive than standard care.

The bigger reason men get tested, in practice, is their daughters. A man whose mother carried a BRCA1 variant is the essential link in the chain: if he tests negative, his children don’t need testing at all. If he tests positive, his daughters gain access to screening starting at 25. Testing a father can spare, or protect, an entire generation.

Is the BRCA test covered by insurance, and can results be used against you?

For most people who meet risk criteria, yes. Under the Affordable Care Act, BRCA risk assessment, genetic counseling, and testing carry a U.S. Preventive Services Task Force “B” recommendation for women with qualifying personal or family history, which means most private insurance plans must cover them as preventive care with no out-of-pocket cost. Medicare and Medicaid coverage rules differ and generally hinge on personal cancer history or documented family risk, so it’s worth a call before scheduling.

If you don’t meet criteria, or your plan balks, self-pay prices have fallen dramatically, from thousands of dollars a decade ago to a few hundred at many clinical laboratories today. A genetic counselor can tell you the realistic out-of-pocket range before you commit.

Now the question people ask in a lower voice: can a positive result be used against me? Here’s what the law actually says. The Genetic Information Nondiscrimination Act of 2008 (GINA) prohibits health insurers from using genetic results to deny coverage or raise premiums, and bars employers with 15 or more workers from using them in hiring or firing decisions.

The honest gap: GINA does not cover life insurance, disability insurance, or long-term care insurance. Those insurers can legally ask about genetic test results in most states. Genetic counselors routinely mention this, and some people choose to arrange those policies before testing. It’s a legitimate consideration, not a reason to avoid information that could protect your health, but a reason to sequence your paperwork thoughtfully.

Should you trust an at-home DNA kit for BRCA?

Treat consumer DNA kits as a conversation starter, never a conclusion. Some popular at-home services report on BRCA, but typically only on three specific “founder” variants most common in people of Ashkenazi Jewish descent. Clinical laboratories, by contrast, sequence both genes end to end and can detect thousands of distinct harmful variants, plus large deletions and rearrangements that consumer chips miss entirely.

The math makes the problem obvious. If you’re not of Ashkenazi ancestry, those three variants account for a small fraction of harmful BRCA changes, meaning a “no variants detected” report can be deeply false reassurance. Someone with a textbook high-risk family history could receive a clean consumer report while carrying a variant the kit was never designed to find.

The reverse error happens too. Raw-data files from ancestry services, run through third-party interpretation tools, have produced false-positive BRCA calls that dissolved on clinical retesting. That’s why the standard advice from genetics professionals is firm on both sides:

• Never make a medical decision based on a consumer kit result, positive or negative.
• Any concerning consumer finding should be confirmed with a clinical-grade test ordered through a healthcare provider.
• A reassuring consumer result does not replace testing if your family history meets clinical criteria.

If a kit result is what got you thinking about hereditary cancer at all, that’s a genuinely useful outcome, as long as the next step is a counselor’s office, not a decision.

When to see a doctor

Two separate triggers deserve a clear line here, one about your family tree, one about your body.

See a doctor about genetic risk assessment if:

• Any close relative had breast cancer before 50, ovarian cancer at any age, male breast cancer, pancreatic cancer, or metastatic prostate cancer
• Cancer clusters on one side of your family across generations
• You have Ashkenazi Jewish ancestry and any family history of these cancers
• A relative has already tested positive for a BRCA or related variant
• You had cancer yourself and were never offered genetic testing, criteria have broadened considerably in the past decade

See a doctor promptly, regardless of any gene test result, if you notice:

• A new lump or thickening in the breast, chest, or underarm
• Nipple discharge, retraction, or skin changes such as dimpling or redness
• Persistent bloating, pelvic or abdominal pain, feeling full quickly, or urinary urgency lasting more than a couple of weeks: the quiet cluster associated with ovarian cancer
• Unexplained weight loss, jaundice, or new upper-abdominal pain

That second list matters even for people with negative genetic results. A gene test estimates future risk; it says nothing about what’s happening in your body right now. Symptoms always outrank statistics: a clean BRCA report is never a reason to wait out a lump.

Telling your family: the part nobody prepares you for

Ask genetic counselors what patients struggle with most, and the answer usually isn’t the result. It’s the phone calls afterward. A positive BRCA test is, by its nature, family news: every sibling has a 50% chance of carrying the same variant, every child does too, and cousins on the affected side suddenly have information they may or may not want.

The evidence on cascade testing is sobering, studies consistently find that fewer than half of at-risk relatives end up getting tested, often because the news never reached them clearly, or arrived without a roadmap. A few things demonstrably help:

• Ask your genetic counselor for a family lettera standardized document naming the specific variant, which relatives should consider testing, and how to arrange it. Nearly all clinics provide one, and it spares you from playing medical translator.
• Share the exact variant name. “I have the BRCA thing” forces relatives into full-price, full-panel testing; the precise variant makes their test targeted, cheaper, and definitive.
• Expect uneven reactions. Some relatives will test within a month; others will decline for years. Both are legitimate choices about their own bodies, and pressure rarely changes minds.

Give yourself the same grace. It’s normal for a positive result to stir grief, guilt about children, or unexpected relief at finally having an explanation. Genetic counselors are trained for exactly these conversations, and a follow-up session weeks after results, once the dust settles, is one of the most underused resources in the entire process.

Frequently asked questions

Is the BRCA test covered by insurance?

Usually, yes, if you meet risk criteria. For women with a qualifying personal or family history, the Affordable Care Act requires most private plans to cover BRCA counseling and testing as preventive care with no cost-sharing. Medicare and Medicaid rules vary and often require a personal cancer history or documented family risk. Without coverage, self-pay clinical testing has dropped to a few hundred dollars at many laboratories.

At what age should you be tested for the BRCA gene?

Most people at elevated risk are tested between 18 and their early 30s, because carrier screening, annual breast MRI, begins at age 25, and knowing your status by then keeps you from missing that window. Testing minors is generally discouraged since results change nothing before adulthood. Testing remains worthwhile at any adult age, both for your own prevention options and for informing children and grandchildren.

Which parent passes the BRCA gene?

Either parent can pass it. BRCA1 and BRCA2 sit on ordinary chromosomes inherited equally from mothers and fathers, and each child of a carrier, son or daughter, has a 50% chance of inheriting the variant. Fathers often carry it silently because their associated cancers, such as prostate cancer, are less visibly linked to genetics, which lets variants travel unnoticed through the paternal side for generations.

What happens if a BRCA test is positive?

You gain options, not a diagnosis. Typical next steps include intensified screening, breast MRI from age 25 with mammography added around 30, plus discussions about risk-reducing surgery, which can lower breast cancer risk by roughly 90% or more, and preventive medication options. Your close relatives are offered targeted cascade testing, since each has a 50% chance of carrying the same variant. Many carriers never develop cancer at all.

Does a positive BRCA test mean I will definitely get cancer?

No. A positive result means elevated risk, not certainty. Even at the high end, BRCA1 carriers face a 55–72% lifetime breast cancer risk, a meaningful share of carriers never develop the disease. Risk also varies with the specific variant, family history, and lifestyle factors. What the result reliably does is unlock earlier screening and prevention options that substantially improve the odds of catching or avoiding cancer.

Can men carry and be affected by BRCA mutations?

Yes, on both counts. Men carry BRCA variants at the same rate as women and pass them to children at the same 50% odds. A BRCA2 variant raises a man’s lifetime breast cancer risk to roughly 6–7%, about 60 times the average, and increases risks of prostate cancer, which tends to be more aggressive in carriers, and pancreatic cancer. Positive men typically start earlier prostate screening conversations around age 40.

What does a 'variant of uncertain significance' mean?

It means the lab found a genetic change that science can’t yet classify as harmful or harmless. The firm professional consensus: don’t make any medical decision based on a VUS, because when these variants are eventually reclassified, the large majority prove benign. Keep your contact information current with the testing lab, check back every couple of years, and base screening on your family history in the meantime.

If my mother has a BRCA mutation and I test negative, am I safe?

That situation, called a true negative, is genuinely reassuring. Because the lab checked you for your family’s specific known variant and didn’t find it, your cancer risk returns to roughly the general population’s, and standard screening guidelines apply. You also cannot pass on a variant you don’t carry, so your children don’t need testing for it. Ordinary risk still exists, so routine screening remains important.

How long do BRCA test results take?

Clinical BRCA testing typically returns results in two to four weeks, though some laboratories report sooner and complex cases can take longer. When a specific family variant is already known, targeted testing for relatives is often faster. Results are usually delivered through a genetic counselor or ordering clinician rather than a raw report, so the explanation of what the finding means arrives with the result itself.

Can an at-home DNA kit reliably rule out BRCA mutations?

No. Popular consumer kits typically check only three founder variants most common in Ashkenazi Jewish populations, while clinical labs sequence both genes fully and detect thousands of harmful changes plus large rearrangements. A clean consumer report can therefore be false reassurance, especially for people of other ancestries. Any concerning kit finding, and any strong family history, regardless of kit results, warrants clinical-grade testing ordered through a healthcare provider.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.